Aion Therapeutic Inc. (AION.CN)
| Previous Close | 0.0150 |
| Open | 0.0150 |
| Bid | 0.0100 x N/A |
| Ask | 0.0150 x N/A |
| Day's Range | 0.0150 - 0.0150 |
| 52 Week Range | 0.0100 - 0.0800 |
| Volume | |
| Avg. Volume | 65,679 |
| Market Cap | 2.127M |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0560 |
| Earnings Date | Sept 30, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes
Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer
- Newsfile
Aion Therapeutic Files Financials
Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").Management of the Company has been subject to a management cease trade order (the "MCTO") in respect of the securities of the Company issued by the applicable securities ...
- CNW Group
Aion Therapeutic Provides Default Status Update
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 14, 2021 and September 28, 2021, the Company is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").
